Made available in DSpace on 2014-07-29T15:30:36Z (GMT). No. of bitstreams: 1 Dissertacao Andrea Alves Ribeiro.pdf: 1577076 bytes, checksum: 24bc7ace843786b03ff879da0df4f7aa (MD5) Previous issue date: 2009-12-15 / Human papillomavirus (HPV) is considered the central etiological agent involved in the genesis of cervical cancer. The HPV viruses are classified according to their biological niche, oncogenic potential and phylogenetic position. According to the criteria established by the International Committee on Taxonomy of Viruses (ICTV), the various groups of human papillomaviruses that infect the female genital tract are classified phylogenetically in the Alphapapillomavirus genus, including species classified among phylogenetic species 1 and species 15. The main high risk HPV are classified in species 9 (HPV 16, 31, 33, 35, 52, 58, 67), and in species 7 (18, 39, 45, 59, 56, 66, 68 and 70). HPV 16 is the most prevalent type irrespective of diagnosis, principally in more severe lesions. Coinfection with multiple-types HPV is a common finding of many molecular studies. Some HPV types might interact or act synergistically to induce progression. Few studies have investigated the interactions of viral genotypes or species in multiple-type HPV infections. Therefore, the objective of this study was to evaluate the effect of single or multiple-types HPV infections considering also the phylogenetic groups on the prevalence and severity of cervical intraepithelial neoplasia (CIN) among women undergoing colposcopy following a abnormal cervical smear. Methodology: In this analysis, 198 women attending at the colposcopic clinic, because of an abnormal cervical smear were included. Colposcopy was carried out in all cases and biopsies were done in 193 of 198 women included. All specimens were tested for 27 HPV genotypes by Roche s polymerase chain reaction reverse line blot assay. Results: The overall prevalence of HPV in women with an abnormal cervical smear was 86% (171/198). Of the total of HPV-positive women, 45% (77/171) were infected with HPV 16 as a single or multiple-type infections. HPV 31 and 35 were, respectively, the second and third most prevalent types. The prevalence of HPV 16 in high grade cervical intraepithelial neoplasia (CIN2/3) was 52% (40/76) and it was detected in 88.8% (8/9) in cases of invasive carcinoma. The prevalence of type 31 and 35 in high grade CIN was respectively 10.5% (8/76) and 6.6% (5/76). Single HPV infection for any type was significantly associated with neoplastic diagnosis. High grade neoplastic diagnosis (≥ CIN2) was significantly associated with HPV 16 in single or multiple infections. Also, there was significantly association between HPV 16 and others types of specie 9 and high grade neoplastic diagnosis, but no association was observed considering the HPV 16 and other of groups of species 7 or others types. Conclusion: These results indicated that the type 16 is the most important predictor of high grade cervical neoplasia. Multiple-type infections are predictors of high grade cervical neoplasia when the type 16 is present. / O Papilomavírus humano (HPV) é considerado o agente etiológico central envolvido na gênese do câncer cervical. O vírus HPV é classificado de acordo com seu nicho biológico, potencial oncogênico e classificação filogenética. De acordo com os critérios estabelecidos pelo Comitê Internacional de Taxonomia dos Vírus (ICTV), os diversos tipos de HPV que infectam o trato genital feminino são classificados filogeneticamente no gênero Alphapapillomavirus. Esta classificação inclui espécies filogenéticas classificadas entre a espécie 1 e a espécie 15, dentre as quais, as de maior interesse em relação ao potencial carcinogênico são a espécie 9 (HPV 16, 31, 33, 35, 52, 58, 67) e a espécie 7 (18, 39, 45, 56, 59, 66, 68, 70). O HPV 16 é tipo o mais predominante, independente do diagnóstico, presente principalmente nas lesões cervicais mais graves. A co-infecção com múltiplos tipos de HPV é um achado comum em muitos estudos moleculares, contudo, as interações dos genótipos virais ou espécies envolvidas nas infecções por múltiplos tipos de HPV têm sido pouco analisadas. Portanto, o objetivo deste estudo foi avaliar o efeito das infecções simples ou por múltiplos tipos de HPV, considerando também os grupos filogenéticos, sobre a prevalência e a gravidade das neoplasias cervicais. Metodologia: Este estudo de corte transversal incluiu 198 mulheres encaminhadas ao Ambulatório de Colposcopia da Santa Casa de Misericórdia de Goiânia por exame citopatológico anormal. Todas as mulheres foram esclarecidas quanto aos objetivos de estudo e assinaram o termo de consentimento livre e esclarecido. A colposcopia foi realizada em todos os casos e a biópsia em 193 das 198 mulheres incluídas. As amostras foram testadas para 27 genótipos de HPV, por reação em cadeia da polimerase (PCR); em seguida foi realizada a hibridização reversa em pontos da Roche Diagnósticos. Resultados: A prevalência de HPV em mulheres encaminhadas por exame citopatológico anormal foi de 86% (171/198). Do total de mulheres HPV-positivas, 45% (77/171) estavam infectadas por HPV 16 em infecções simples e múltiplas. Os tipos de HPV 31 e 35 foram respectivamente, o segundo e o terceiro mais prevalentes. A prevalência do HPV 16 foi de 52% (40/76) nas neoplasias intra-epiteliais cervicais de alto grau (NIC 2/3) e de 88,8% (8/9) nos casos de carcinomas invasivos. As prevalências dos tipos 31 e 35 em neoplasias intra-epiteliais cervicais de alto grau (NIC 2/3) foram de 10,5% (8/76) e 6,6% (5/76), respectivamente. A infecção simples por qualquer tipo de HPV foi significativamente associada com diagnósticos neoplásicos de alto grau (≥ NIC 2). Os diagnósticos neoplásicos de alto grau (≥ NIC 2) foram significativamente associados com o HPV 16 em infecções simples ou múltiplas, mesmo depois de ajustado pela positividade para DNA de HPV. Houve significativa associação entre o HPV 16 e outros tipos da espécie 9 e os diagnósticos neoplásicos de alto grau (≥ NIC 2), mas não foi observada associação, considerando o HPV 16 e outros tipos da espécies 7 ou outros tipos de HPV. Conclusão: Estes resultados indicam que o HPV 16 parece ser o mais importante preditor de diagnósticos neoplásicos de alto grau. As infecções múltiplas são preditoras das neoplasias cervicais de alto grau quando o HPV 16 está presente.

Submitted by Nadir Basilio (nadirsb@uninove.br) on 2016-05-17T21:35:19Z No. of bitstreams: 1 Mario Cezar Saffi Junior.pdf: 600477 bytes, checksum: 389162272a6d7d9eb1d1a097d21a6d9a (MD5) / Made available in DSpace on 2016-05-17T21:35:19Z (GMT). No. of bitstreams: 1 Mario Cezar Saffi Junior.pdf: 600477 bytes, checksum: 389162272a6d7d9eb1d1a097d21a6d9a (MD5) Previous issue date: 2015-01-22 / The cervical cancer is the first cancer of the female genital tract in Brazil and HPV is essential factor for carcinogenesis. The Brazilian program tracking proposes conventional cervical cytology as the primary method to detect cervical cancer, despite its low sensitivity. Risk factors associated with the spread of HPV are despised and not rely on a biomolecular tool that can increase the program offered by the Ministry of Health. The aim of this study was to determine whether the risk factors for cervical cancer may contribute to the conventional cervical cytology to increase diagnostic sensitivity and assess whether the mRNA indoleamine 2,3 dioxygenase (IDO) and mRNA CDKN2A / p16 may increase the diagnostic yield of this neoplasm. The logistic regression analysis was based on clinical variables (risk factors), cytological and biomolecular to seek an association with pathological results. The proportion of explained variance (PVE) for each variable studied was calculated by the formula omega, whereas the sensitivity, specificity, positive predictive value and negative predictive value were calculated by the formulas of Galen and Gambino. We conclude that oral contraceptive showed greater predictive power of high-grade lesions compared to other risk factors, and that both the IDO mRNA as CDKN2A mRNA / p16 may help screening of cervical cancer, either when used alone, or in conjunction with conventional cervical cytology, increasing their sensitivity and maintaining a considerable specificity. / O câncer de colo uterino apresenta-se como a principal neoplasia do trato genital feminino no Brasil, sendo o HPV fator essencial para a carcinogênese. O programa brasileiro de rastreamento propõe a citologia oncológica cervical convencional como principal método para detectar o câncer do colo uterino, apesar da sua baixa sensibilidade. Os fatores de risco associados ao contágio do HPV são desprezados e não contamos com uma ferramenta biomolecular que possa incrementar o programa oferecido pelo Ministério da Saúde. O objetivo desse trabalho foi verificar se os fatores de risco para o câncer de colo uterino podem contribuir com a citologia oncológica cervical convencional para aumentar a sensibilidade diagnóstica e avaliar se o RNAm Indoleamine 2,3 dioxigenase (IDO) e o RNAm CDKN2A/p16 podem incrementar a capacidade diagnóstica dessa neoplasia. A análise de regressão logística foi baseada nas variáveis clínicas (fatores de risco), citológicas e biomoleculares a fim de buscar uma associação com o resultado anatomopatológico. A proporção de variação explicada (PVE) por cada uma das variáveis estudada foi calculada pela fórmula ômega, enquanto que a sensibilidade, especificidade, valor preditivo positivo e o valor preditivo negativo foram calculados pelas fórmulas de Galen e Gambino. Concluímos que o uso do contraceptivo oral mostrou um maior poder de predição de lesões de alto grau em relação aos demais fatores de risco, e que tanto a RNAm IDO quanto o RNAm CDKN2A/p16 poderem auxiliar no rastreamento do câncer de colo uterino, seja quando usados de forma isolada, seja conjuntamente com a citologia cervical convencional, elevando sua sensibilidade e mantendo uma considerável especificidade.

Pancreatic cancer is still a dismal disease. The high mortality rate is mainly caused by the lack of highly sensitive and specific diagnostic tools, and most of the patients are diagnosed in an advanced and incurable stage. Knowledge about precursor lesions for pancreatic cancer has grown significantly over the last decade, and nowadays we know that mainly three lesions (PanIN, and IPMN, MCN) are responsible for the development of pancreatic cancer. The early detection of these lesions is still challenging but provides the chance to cure patients before they might get an invasive pancreatic carcinoma. This paper focuses on PanIN, IPMN, and MCN lesions and reviews the current level of knowledge and clinical measures.

Objectif : Les traitements répétés des lésions précancéreuses du col utérin (HSIL), nécessaires en cas d’échecs de traitement, sont associés à des issues obstétriques négatives, telle qu’une augmentation de la mortalité néonatale. Nous avons investigué l’association entre un grand nombre de facteurs de risque potentiels pour l’échec de traitement des HSIL dans le but d’identifier des prédicteurs potentiellement modifiables de l’échec de traitement. Méthodes : La population source était constituée de 1 548 femmes canadiennes qui ont subi un premier traitement pour HSIL. L’échec de traitement a été défini comme étant un diagnostic histologique de HSIL ou cancer au cours des deux années suivant le traitement. Nous avons mené une étude cas-témoins nichée incluant les 101 cas d’échec de traitement ainsi que les témoins appariés 1 :1 par centre de traitement et par date d’échec. Nous avons calculé des rapports de cotes (OR) et intervalles de confiance (CI) à 95% à l’aide de régressions logistiques conditionnelles, pour les associations entre l’échec de traitement et l’âge, le nombre d’accouchements, le statut tabagique, le nombre de partenaires sexuels, l’utilisation du condom, la méthode de contraception, les marges, le nombre de passages, le diagnostic sur le spécimen de traitement, le génotype du VPH, et le nombre de types. Nous avons aussi estimé l’association entre la charge virale et les variants du VPH16 et du VPH18 et l’échec de traitement. Résultats : Les marges positives vs négatives (OR ajusté=4.05, 95% CI 1.57-10.48), la positivité pour le VPH16/18 vs autres types (OR ajusté=2.69, 95% CI 1.32-5.49), et avoir un variant similaire au prototype du VPH16 vs le prototype (OR ajusté=2.49, 95% CI 1.07-5.83) étaient des prédicteurs de l’échec de traitement des HSIL. Être plus âgé, avoir des lésions plus sévères, avoir une infection monotype, et avoir une variation à la position 7521 chez celles avec le VPH16 pourraient augmenter le risque d’échec de traitement, mais les associations n’étaient pas statistiquement significatives. Les estimations pour les autres facteurs étaient proches de la valeur nulle. Nous n’avons pas observé de modification d’effet du génotype sur le risque de l’échec de traitement par le tabagisme, ni par les marges. Conclusion : Seules les marges positives, la positivité pour le VPH16/18 et avoir un variant similaire au prototype étaient des prédicteurs d’un échec de traitement au cours des deux années suivant le traitement. Malgré l’aspect non-modifiable des prédicteurs identifiés, ils sont informatifs et pourront éclairer la prise en charge et le suivi clinique. / Objective: Repeated treatments for high-grade squamous intraepithelial lesions (HSIL), which are necessary in the case of treatment failure, are associated with negative obstetric outcomes, such as an increased risk of neonatal death. We investigated the association between a large number of potential risk factors and HSIL treatment failure in an effort to identify potentially modifiable predictors of treatment failure. Methods: The source population included 1,548 Canadian women who received a first treatment for HSIL. Treatment failure was defined as the histological diagnosis of HSIL or cancer within the two years following treatment. We conducted a nested case-control study that included all 101 cases of treatment failure and controls that were matched 1:1 on treatment center and date of failure. We used conditional logistic regression to calculate the odds ratios (OR) and 95% confidence intervals (CI) between treatment failure and age, parity, smoking status, number of sexual partners, condom use, method of contraception, margins, number of passes, diagnosis on the treatment specimen, HPV genotype and number of types. We also estimated the association between HPV16 and HPV18 viral loads and variants and HSIL treatment failure. Results: Having positive vs. negative margins (adjusted OR=4.05, 95% CI 1.57-10.48), being positive for HPV16 and/or HPV18 vs. any other type (adjusted OR=2.69, 95% CI 1.32-5.49), and having a prototype-like variant of HPV16 vs. the prototype (adjusted OR=2.49, 95% CI 1.07-5.83) were predictors of HSIL treatment failure. Older age, more severe lesions, single-type infections and a variation at the 7521 position of the HPV16 genetic sequence may lead to a higher risk of treatment failure but were not statistically significant. Estimates for all other factors were near the null value. The effect of genotype on the risk of treatment failure was not modified by smoking status, nor by margin status. Conclusion: Only positive margins, HPV16/18 positivity, and having a prototype-like variant of HPV16 were predictors for HSIL treatment failure within two years of treatment. Despite being non-modifiable, the identified predictors are clinically significant in regards to management and follow-up of patients.

OBJETIVO: O objetivo deste estudo foi analisar a concordância entre o esfregaço anal e a biópsia guiada por anuscopia de alta resolução no diagnóstico da displasia anal em pacientes infectados pelo HIV. MÉTODO: Conduzimos uma análise transversal de pacientes infectados pelo HIV submetidos a rastreamento de displasia anal rotineiro. A concordância entre mensurações foi estimada por índice de kappa ponderado através de sistema de avaliação citológica e histológica de três categorias (normal, displasia de baixo grau, e displasia de alto grau). Estimativas de sensibilidade, especificidade e valores preditivos foram calculados através de sistema de avaliação citológica e histológica de duas categorias (ausência de displasia e displasia de qualquer grau). Estimativas foram calculadas também para a detecção de displasia de alto grau. RESULTADOS: No decorrer de um ano, 222 pacientes foram submetidos a 330 esfregaços anais seguidos de biópsias guiadas por anuscopia de alta resolução. Trezentos e onze (311) esfregaços com biópsias concomitantes foram satisfatórios. Considerando-se a histologia como padrão, a freqüência de displasia anal foi de 46%. O índice kappa ponderado para concordância entre o esfregaço anal e a biópsia foi de 0,20. Para detecção de displasia anal de qualquer grau, o esfregaço anal demonstrou sensibilidade de 61%, especificidade de 60%, valor preditivo positivo de 56% e valor preditivo negativo de 64%. Para displasia de alto grau, o esfregaço anal demonstrou sensibilidade de 16% e especificidade de 97%. CONCLUSÃO: Os resultados obtidos no presente estudo, em que comparamos os achados da citologia dos esfregaços com os achados histológicos das biópsias dirigidas pela anuscopia de alta resolução em pacientes infectados pelo HIV permitiram concluir que houve baixa concordância entre eles / Purpose: To analyze the agreement between anal Pap smear and high resolution anoscopy guided biopsy to diagnose anal dysplasia in HIV-infected patients. Methods: Cross sectional analysis of HIV-infected patients receiving anal dysplasia screening as part of routine care. Agreement between measures was estimated by weighted kappa-statistics, using 3-tiered cytologic and histologic grading system (normal, low grade dysplasia, and high grade dysplasia). Estimates of sensitivity, specificity, and predictive values were calculated using a 2-tiered cytologic and histologic grading system (without dysplasia, and with dysplasia of any grade). Estimates were also calculated for the detection of high grade dysplasia. Results: Two hundred and twenty-two patients underwent 330 anal Pap smears followed by high resolution anoscopy guided biopsies in one year period. There were 311 satisfactory Pap smears with concurrent biopsy. Considering histology the standard, the frequency of anal dysplasia was 46 percent (95 percent confidence interval: 40-51 percent). Kappa-agreement between anal Pap smear and biopsy was 0.20 (95 percent confidence interval: 0.10 0.29). Anal Pap smear showed sensitivity of 61 percent, specificity of 60 percent, positive predictive value of 56 percent, and negative predictive value of 64 percent for detection of anal dysplasia of any grade. For high grade dysplasia, anal Pap smear showed sensitivity of 16 percent, and specificity of 97 percent. Conclusion: The present study showed a low concordance between anal Pap smears and high resolution anoscopy-guided biopsy

At present, prostate cancer is a significant public health issue throughout the world and is the second leading cause of cancer deaths in older men. The prostate specific antigen or PSA (which is encoded by the kallikrein 3/KLK3 gene) test is the current most valuable tool for the diagnosis and management of prostate cancer. However, it is insufficiently sensitive and specific for early diagnosis, for staging of prostate cancer or for discriminating between benign prostatic hyperplasia (BPH) and prostate cancer. Recent research has revealed another potential tumour marker, glandular kallikrein 2 (KLK2 gene/hK2 protein), which may be used alone or in conjunction with PSA to overcome some of the limitations of the PSA test. Twelve new kallikrein gene family members have been recently identified and, like hK2 and PSA, many of these genes have been suggested to be involved in carcinogenesis. In this study, the cellular localisation and level of expression of several of these newer kallikreins (KLK4, KLK5, KLK7, KLK8 and KLK11) was examined in prostate tissue, to provide an understanding of the association of their expression with prostatic diseases and their potential as additional biomarkers. Like PSA and hK2, the present observation indicated that each of these proteins, hK4, hK5, hK7, hK8 and hK11, was detected within the cytoplasm of the secretory cells of the prostate glands. For the first time, all of these newly-identified proteins were shown to be expressed in prostatic intraepithelial neoplasia (PIN) lesions, in comparison to normal glands and cancer lesions. In addition to cytoplasmic secretory cell expression, the localisation of hK4 to the basal cells and nuclei in prostatic lesions was intriguing. The intensity of hK4 staining in prostate tissue was strongest in comparison to the other newly-identified kallikrein proteins (hK5, hK7, hK8 and hK11). Therefore, KLK4/hK4 expression was characterised further to define this cellular localisation and examined in non-prostatic tissue and also in a larger number of prostate tissues in an attempt to determine its potential value as a biomarker for prostate disease. Three hK4 antipeptide polyclonal antibodies, derived against N-terminal, mid-region and C-terminal hK4 amino acid sequences, were used. The hK4 N-terminal antipeptide antibody was used to demonstrate the cellular localisation of hK4 in kidney, salivary glands, liver, testis, colon carcinoma, heart, endometrium and ovarian cancer, for the first time. The presence of hK4 in these non-prostate tissues was consistent with the previous reports using RT-PCR. The dual cytoplasmic and nuclear localisation of hK4 observed in the prostate above was also seen in these tissues. Although hK4 was found widely expressed in many human tissue types, indicating that it is not prostate specific in its expression, the highest expression level of hK4 was seen in the prostate. Therefore, detailed expression patterns and levels of KLK4 mRNA and hK4 protein in the normal prostate and prostatic diseases and histopathological lesions were investigated and reported for the first time in this study. Twelve benign prostatic hyperplasia (BPH), 19 adenocarcinoma (Gleason grade 2-5) and 34 bone metastases from prostate cancer were analysed. Using in situ hybridisation, the expression of KLK4 mRNA was detected in the cytoplasm of the secretory cells of both normal and diseased prostate tissue. KLK4 mRNA was also noted in both secretory and basal cells of PIN lesions, but the basal cells of normal glands were negative. Using the hK4 N-terminal and mid-region antipeptide antibodies, hK4 was predominantly localised in the cytoplasm of the secretory cells. The intensity of hK4 staining appeared lowest in normal and BPH, and increased in PIN lesions, high Gleason grade prostate cancer and bone metastases indicating the potential of hK4 as a histopathological marker for prostatic neoplasias. Further studies are required with a larger cohort to determine its utility as a clinical biomarker. Small foci of atypical cells, which were found within normal glands, were also intensely stained. Surprisingly, hK4 protein was found in the nucleus of the secretory cells (but not the basal cells) of high grade PIN and Gleason grade 3 prostate cancer. The detection of KLK4 mRNA and hK4 protein in PIN lesions and small foci of atypical cells suggests that up-regulation of KLK4 expression occurs early in the pathology of prostate carcinogenesis. The finding of basal cell expression is not typical for the kallikreins and it is not clear what role hK4 would play in this cell type. With the use of the hK4 C-terminal antipeptide antibody, the staining was mainly localised in the nuclei of the secretory cells of the prostate glands. Although the nuclear localisation was readily noted in more than 90% of epithelial cells of the prostate gland with the C-terminal antibody, no difference in staining intensity was observed among the histopathological lesions of the prostate. The prominent nuclear localisation with the C-terminal antipeptide antibody was also shown to be distributed throughout the nucleus by using confocal microscopy. Further, by using gold-labelled particles for electron microscopy, the intracellular localisation of these hK4 antipeptide antibodies was reported here for the first time. Similar to the immunohistochemical results, the cytoplasm was the major site of localisation with the N-terminal and mid-region antipeptide antibodies. To further characterise the involvement of KLK4/hK4 in human prostate cancer progression, the transgenic adenocarcinoma mouse prostate (TRAMP) model was used in this study. In this study, mouse KLK4 (also known as enamel matrix serine protease -1, EMSP-1) was shown to be expressed in the TRAMP prostate for the first time. Previous studies had only shown the developing tooth as a site of expression for EMSP-1. The level of EMSP-1 mRNA expression was increased in PIN and prostate cancer lesions of the TRAMP model, while negative or low levels of EMSP-1 mRNA were seen in normal glands or in control mouse prostate tissue. The normal mouse prostate did not stain with any the three hK4 antipeptide antibodies. hK4 N-terminal and mid-region antipeptide antibodies showed positive staining in the cytoplasm of the epithelial cells of PIN and cancer lesions of the mouse prostate. The C-terminal antipeptide antibody showed distinctively nuclear staining and was predominantly localised in the nuclei of the glandular cells of PIN and cancer lesions of the mouse prostate. The expression patterns of both the mRNA and protein level for mouse KLK4 strongly supported the observations of KLK4/hK4 expression in the human prostate and further support the utility of the TRAMP model. Overall, the findings in this thesis indicate a clear association of KLK4/hK4 expression with prostate cancer progression. In addition, several intriguing findings were made in terms of cellular localisation (basal as well as secretory cells; nuclear and cytoplasmic) and high expression in atypical glandular cells and PIN, perhaps indicating an early involvement in prostate disease progression and, additionally, utility as basal cell and PIN histological markers. These findings provide the basis for future studies to confirm the utility of hK4 as a biomarker for prostate cancer progression and identify functional roles in the different cellular compartments.

OBJETIVO: O objetivo deste estudo foi analisar a concordância entre o esfregaço anal e a biópsia guiada por anuscopia de alta resolução no diagnóstico da displasia anal em pacientes infectados pelo HIV. MÉTODO: Conduzimos uma análise transversal de pacientes infectados pelo HIV submetidos a rastreamento de displasia anal rotineiro. A concordância entre mensurações foi estimada por índice de kappa ponderado através de sistema de avaliação citológica e histológica de três categorias (normal, displasia de baixo grau, e displasia de alto grau). Estimativas de sensibilidade, especificidade e valores preditivos foram calculados através de sistema de avaliação citológica e histológica de duas categorias (ausência de displasia e displasia de qualquer grau). Estimativas foram calculadas também para a detecção de displasia de alto grau. RESULTADOS: No decorrer de um ano, 222 pacientes foram submetidos a 330 esfregaços anais seguidos de biópsias guiadas por anuscopia de alta resolução. Trezentos e onze (311) esfregaços com biópsias concomitantes foram satisfatórios. Considerando-se a histologia como padrão, a freqüência de displasia anal foi de 46%. O índice kappa ponderado para concordância entre o esfregaço anal e a biópsia foi de 0,20. Para detecção de displasia anal de qualquer grau, o esfregaço anal demonstrou sensibilidade de 61%, especificidade de 60%, valor preditivo positivo de 56% e valor preditivo negativo de 64%. Para displasia de alto grau, o esfregaço anal demonstrou sensibilidade de 16% e especificidade de 97%. CONCLUSÃO: Os resultados obtidos no presente estudo, em que comparamos os achados da citologia dos esfregaços com os achados histológicos das biópsias dirigidas pela anuscopia de alta resolução em pacientes infectados pelo HIV permitiram concluir que houve baixa concordância entre eles / Purpose: To analyze the agreement between anal Pap smear and high resolution anoscopy guided biopsy to diagnose anal dysplasia in HIV-infected patients. Methods: Cross sectional analysis of HIV-infected patients receiving anal dysplasia screening as part of routine care. Agreement between measures was estimated by weighted kappa-statistics, using 3-tiered cytologic and histologic grading system (normal, low grade dysplasia, and high grade dysplasia). Estimates of sensitivity, specificity, and predictive values were calculated using a 2-tiered cytologic and histologic grading system (without dysplasia, and with dysplasia of any grade). Estimates were also calculated for the detection of high grade dysplasia. Results: Two hundred and twenty-two patients underwent 330 anal Pap smears followed by high resolution anoscopy guided biopsies in one year period. There were 311 satisfactory Pap smears with concurrent biopsy. Considering histology the standard, the frequency of anal dysplasia was 46 percent (95 percent confidence interval: 40-51 percent). Kappa-agreement between anal Pap smear and biopsy was 0.20 (95 percent confidence interval: 0.10 0.29). Anal Pap smear showed sensitivity of 61 percent, specificity of 60 percent, positive predictive value of 56 percent, and negative predictive value of 64 percent for detection of anal dysplasia of any grade. For high grade dysplasia, anal Pap smear showed sensitivity of 16 percent, and specificity of 97 percent. Conclusion: The present study showed a low concordance between anal Pap smears and high resolution anoscopy-guided biopsy